Smoking cessation aids 2012

Back to list of bulletin subject headings.

Research from 18 May 2012

  • Beard, E., Aveyard, P., McNeill, A., Michie, S., Fidler, J. A., Brown, J., and West, R. Mediation analysis of the association between use of NRT for smoking reduction and attempts to stop smoking. Psychol.Health . 14-5-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22583084
  • McClure, E. A., Vandrey, R. G., Johnson, M. W., and Stitzer, M. L. Effects of Varenicline on Abstinence and Smoking Reward Following a Programmed Lapse. Nicotine.Tob.Res.  9-5-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22573730
  • Papke, R. L., Ono, F., Stokes, C., Urban, J., and Boyd, R. T. The nicotinic acetylcholine receptors of zebrafish and an evaluation of pharmacological tools used for their study. Biochemical Pharmacology . 9-5-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22580045
  • Willems, R. A., Willemsen, M. C., Nagelhout, G. E., and de, Vries H. Understanding Smokers' Motivations to Use Evidence-based Smoking Cessation Aids. Nicotine.Tob.Res.  9-5-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22573725

Research from 11 May 2012

  • Bordia, T., Hrachova, M., Chin, M., McIntosh, J. M., and Quik, M. Varenicline is a potent partial agonist at alpha6beta2* nAChRs in rat and monkey striatum. Journal of Pharmacology and Experimental Therapeutics . 1-5-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22550286
  • Prochaska, J. J. and Hilton, J. F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 344, e2856. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22563098
  • Rucktooa, P., Haseler, C. A., van, Elk R., Smit, A. B., Gallagher, T., and Sixma, T. K. Structural characterization of the binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through the study of ligand complexes with acetylcholine binding protein. Journal of Biological Chemistry . 2-5-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22553201
  • Yoon, J. H., Newton, T. F., Haile, C. N., Bordnick, P. S., Fintzy, R. E., Culbertson, C., Mahoney, J. J., III, Hawkins, R. Y., Labounty, K. R., Ross, E. L., Aziziyeh, A. I., and La Garza, R. D. Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine- and nicotine-dependent volunteers. Addictive Behaviors . 26-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22560371

Research from 27 April 2012

  • Cahill, K., Stead, L. F., and Lancaster, T. Nicotine receptor partial agonists for smoking cessation. Cochrane.Database.Syst.Rev. 4, CD006103. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22513936
  • Etter, J. F. and Schneider, N. G. An Internet Survey of Use, Opinions and Preferences for Smoking Cessation Medications: Nicotine, Varenicline, and Bupropion. Nicotine Tob.Res.  22-4-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22529220
  • Rhodes, J. D., Hawk, L. W., Jr., Ashare, R. L., Schlienz, N. J., and Mahoney, M. C. The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. Psychopharmacology (Berl) . 12-4-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22526531
  • Sand, L., Lekerud, A. K., Wallstrom, M., and Hirsch, J. M. Local Tolerance of a Sublingual Nicotine Tablet, an Open Single-centre Study. In Vivo 26[3], 463-468. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22523300
  • Yousefi, M. K., Folsom, T. D., and Fatemi, S. H. A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. J.Addict.Res.Ther. S4[1]. 20-12-2011. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22514788

Back to top.

Research from 20 April 2012

  • Christalla, P., Dewenter, M., and El-Armouche, A. [Effectiveness and safety of varenicline for smoking cessation.]. Deutsche Medizinische Wochenschrift . 10-4-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22492478
  • McKee, S. A., Weinberger, A. H., Shi, J., Tetrault, J., and Coppola, S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine Tob.Res.  6-4-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22492085
  • Tahiri, M., Mottillo, S., Joseph, L., Pilote, L., and Eisenberg, M. J. Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials. American Journal of Medicine . 11-4-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22502956

Research from 13 April 2012

  • Gass, J. C., Wray, J. M., Hawk, L. W., Mahoney, M. C., and Tiffany, S. T. Impact of varenicline on cue-specific craving assessed in the natural environment among treatment-seeking smokers. Psychopharmacology (Berl) . 4-4-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22476610
  • Lane, N. E., Leatherdale, S. T., Dubin, J. A., and Hammond, D. Student and school characteristics associated with use of nicotine replacement therapy: A multilevel analysis among Canadian youth. Addictive Behaviors . 17-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22475584

Research from 05 April 2012

  • Ditre, J. W., Oliver, J. A., Myrick, H., Henderson, S., Saladin, M. E., and Drobes, D. J. Effects of Divalproex on Smoking Cue Reactivity and Cessation Outcomes Among Smokers Achieving Initial Abstinence. Exp.Clin.Psychopharmacol.  2-4-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22468897
  • Kassem, M. G. and Al Hossaini, A. M. Varenicline. Profiles Drug Subst.Excip.Relat Methodol. 37, 389-411. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22469324

Research from 30 March 2012

  • Berlin, I., Hunneyball, I. M., Greiling, D., Jones, S. P., Fuder, H., and Stahl, H. D. A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Psychopharmacology (Berl) . 27-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22451094

Research from 23 March 2012

  • Kurko, T., Silvast, A., Wahlroos, H., Pietila, K., and Airaksinen, M. Is pharmaceutical policy evidence-informed? A case of the deregulation process of nicotine replacement therapy products in Finland. Health Policy . 12-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22417863

Research from 16 March 2012

  • Lotfipour, S., Mandelkern, M., Alvarez-Estrada, M., and Brody, L. A Single Administration of Low-Dose Varenicline Saturates alpha4beta2(*) Nicotinic Acetylcholine Receptors in the Human Brain. Neuropsychopharmacology . 7-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22395733
  • Lutz, M. A., Lovato, P., and Cuesta, G. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. Hosp.Pract.(Minneap.) 40[1], 24-34. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22406880
  • Lutz, M. A., Lovato, P., and Cuesta, G. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua. Hosp.Pract.(Minneap.) 40[1], 35-43. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22406881
  • Pandhare, A., Hamouda, A. K., Staggs, B., Aggarwal, S., Duddempudi, P. K., Lever, J. R., Lapinsky, D. J., Jansen, M., Cohen, J. B., and Blanton, M. P. Bupropion Binds to Two Sites in the Torpedo Nicotinic Acetylcholine Receptor Transmembrane Domain: A Photoaffinity Labeling Study with the Bupropion Analog [125I]-SADU-3-72. Biochemistry . 6-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22394379
  • Silverstone, P. H. and Dadashova, R. Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. Ann.Gen.Psychiatry 11[1], 6. 9-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22405499

Research from 09 March 2012

  • Bhutani, G., Kaushal, J., and Gupta, M. C. Critical appraisal of the existing and emerging therapies for smoking cessation. Medical Journal of Malaysia 66[5], 526-533. 2011. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22390122
  • Carpenter, M. J., Ford, M. E., Cartmell, K., and Alberg, A. J. Misperceptions of nicotine replacement therapy within racially and ethnically diverse smokers. Journal of the National Medical Association 103[9-10], 885-894. 2011. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22364057
  • Coleman, T., Cooper, S., Thornton, J. G., Grainge, M. J., Watts, K., Britton, J., and Lewis, S. A randomized trial of nicotine-replacement therapy patches in pregnancy. N.Engl.J.Med. 366[9], 808-818. 1-3-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22375972
  • de Dios, M. A., Anderson, B. J., Stanton, C., Audet, D. A., and Stein, M. Project Impact: A pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers. Journal of Substance Abuse Treatment . 27-2-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22377389
  • Stephens, L. A. and Stevermer, J. J. PURLs: Counseling is a must with this smoking cessation aid. Journal of Family Practice 61[3], 156-176. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22393555

Back to top.

Research from 24 February 2012

  • Berlin, I. Varenicline in stopping long-term nicotine use. Am.J.Addict. 21[2], 182-183. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22332865
  • Stead, L. F. and Hughes, J. R. Lobeline for smoking cessation. Cochrane.Database.Syst.Rev. 2, CD000124. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22336780
  • Tranel, D., McNutt, A., and Bechara, A. Smoking Cessation After Brain Damage Does Not Lead to Increased Depression: Implications for Understanding the Psychiatric Complications of Varenicline. Cogn Behav.Neurol.  13-2-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22330182

Research from 17 February 2012

  • Borland, R., Partos, T. R., and Cummings, K. M. Systematic Biases in Cross-sectional Community Studies may Underestimate the Effectiveness of Stop-Smoking Medications. Nicotine Tob.Res.  7-2-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22318689
  • Harrison-Woolrych, M., Harmark, L., Tan, M., Maggo, S., and van, Grootheest K. Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres. European Journal of Clinical Pharmacology . 8-2-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22315148
  • Hu, L., Wang, Z., Xu, R., Ma, J., Wang, X., and Zhang, X. Determination of bupropion and its main metabolite in rat plasma by LC-MS and its application to pharmacokinetics. Pharmazie 66[12], 924-928. 2011. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22312695
  • Tonnesen, P., Lauri, H., Perfekt, R., Mann, K., and Batra, A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double blind trial. Eur.Respir.J.  9-2-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22323576

Research from 10 February 2012

  • Gratziou, C., Gourgoulianis, K., Pataka, P. A., Sykara, G. D., Messig, M., and Raju, S. Varenicline as a smoking cessation aid in a Greek population: a subanalysis of an observational study. Tob.Induc.Dis. 10[1], 1. 2-2-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22300423

Research from 03 February 2012

  • Aschenbrenner, D. S. FDA review of antismoking aid, varenicline, and neuropsychiatric adverse events. American Journal of Nursing 112[2], 28. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22277865
  • Cox, L. S., Nollen, N. L., Mayo, M. S., Choi, W. S., Faseru, B., Benowitz, N. L., Tyndale, R. F., Okuyemi, K. S., and Ahluwalia, J. S. Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial. Journal of the National Cancer Institute . 25-1-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22282543
  • Ferguson, S. G., Gitchell, J. G., and Shiffman, S. Continuing to wear nicotine patches after smoking lapses promotes recovery of abstinence. Addiction . 26-1-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22276996

Research from 27 January 2012

  • Mahmoudi, M., Coleman, C. I., and Sobieraj, D. M. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. International Journal of Clinical Practice 66[2], 171-182. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22257042

Research from 20 January 2012

  • Alpert, H. R., Connolly, G. N., and Biener, L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob.Control . 10-1-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22234781
  • Bailey, S. R., Crew, E. E., Riske, E. C., Ammerman, S., Robinson, T. N., and Killen, J. D. Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents. Paediatr.Drugs . 16-1-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22248234
  • Heydari, G., Talischi, F., Tafti, S. F., and Masjedi, M. R. Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. International Journal of Tuberculosis and Lung Disease 16[2], 268-272. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22236931
  • Huang, Y., Britton, J., Hubbard, R., and Lewis, S. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob.Control . 13-1-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22246781
  • Ortiz, N. C., O'Neill, H. C., Marks, M. J., and Grady, S. R. Varenicline Blocks beta2*-nAChR-Mediated Response and Activates beta4*-nAChR-Mediated Responses in Mice In Vivo. Nicotine Tob.Res.  12-1-2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22241831
  • Takusagawa, H. L., Hunter, R. S., Jue, A., Pasquale, L. R., and Chen, T. C. Bilateral uveal effusion and angle-closure glaucoma associated with bupropion use. Archives of Ophthalmology 130[1], 120-122. 2012. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22232485

Research from 06 January 2012

  • Beard, E., Vangeli, E., Michie, S., and West, R. The Use of Nicotine Replacement Therapy for Smoking Reduction and Temporary Abstinence: An Interview Study. Nicotine Tob.Res.  21-12-2011. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22193570
  • Poghosyan, H., Kennedy, Sheldon L., and Cooley, M. E. The Impact of Computed Tomography Screening for Lung Cancer on Smoking Behaviors: A Teachable Moment? Cancer Nursing . 29-12-2011. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22209869
  • Von, Mulzer K., Dando, S., Gustavsson, G., Radley, N., Sjostedt, G., Sydbom, P., and Waltermo, A. [Improved productcharacteristics of nicotine gums: an unexplored area for higher compliance with nicotine replacement therapy]. MMW.Fortschr.Med. 153 Suppl 3, 75-82. 6-10-2011. Abstract or full text available at: http://www.ncbi.nlm.nih.gov/pubmed/22184800

Back to top.

Back to Smoking cessation aids research 2011.

Back to list of bulletin subject headings.